Skip to main content

Gene Logic s Revenues Up in Q4; Boehringer Ingelheim Renews License

Please click here for an updated version of this article.

 

NEW YORK, Feb. 20 (GenomeWeb News) - Gene Logic reported increased revenues and slightly narrowed losses for the fourth quarter of 2003.

 

Revenues for the quarter increased to $19.7 million, up from $14.8 million during the same period in 2002.

 

R&D costs decreased to $.5 million, from $.8 million during the same quarter a year ago.

 

The company's net loss decreased slightly to $4.9 million, or $.16 per share, from $5.2 million, or $.19 per share, during the fourth quarter a year ago.

 

As of Dec. 31, Gene Logic had approximately $111.8 million in cash, cash equivalents and marketable securities available-for-sale. This includes $48.7 million in cash and cash equivalents.

 

Click here for the full earnings report.

 

Separately, Gene Logic said that Boehringer Ingelheim has renewed its license to Gene Logic's GeneExpress information services for several years.

 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.